MGX
Metagenomi Therapeutics, Inc.
Nasdaq Biological Products, (No Diagnostic Substances)
Emerging growth company

Key Financials

Revenue
$25.2M
↓ 51.8%
Operating Income
$-96013000
↓ 8.0%
Net Income
$-87868000
↓ 12.6%
EPS (Diluted)
$-2.36
0.0%
Total Assets
$221.1M
↓ 31.9%
Shareholders' Equity
$158.6M
↓ 32.5%
Cash & Equivalents
$41.7M
↑ 52.3%
Total Liabilities
$62.5M
↓ 30.3%

Recent SEC Filings

Form Type Filed Date Link
4 6/11/2026 View on SEC
4 6/11/2026 View on SEC
4 6/11/2026 View on SEC
4 6/11/2026 View on SEC
4 6/10/2026 View on SEC
4 6/10/2026 View on SEC
4 6/10/2026 View on SEC
8-K 6/10/2026 View on SEC
10-Q 5/11/2026 View on SEC
8-K 5/11/2026 View on SEC

Company Information

Field Value
Ticker MGX
Company Name Metagenomi Therapeutics, Inc.
CIK 1785279
Sector Biological Products, (No Diagnostic Substances)
Industry
Emerging growth company
Exchange Nasdaq
SIC Code 2836
SIC Description Biological Products, (No Diagnostic Substances)
Entity Type operating
Fiscal Year End 1231
Phone (510) 871-4880